Natural Phenomenon or Process
CSL Announces Vaccine Unit Spin-Off and Major Workforce Cuts
CSL; Seqirus; vaccine spin-off; workforce reduction; demerger; strategic restructuring; biotech; cost-cutting
Fierce Biotech Layoff Tracker 2025: Abata Folds; Generation Lays Off 90% of Staff
biotech layoffs; Abata; Generation; Fierce Biotech Layoff Tracker; 2025; company closure; staff reduction
Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares
Assembly Bio; Phase 1b trial; ABI-5366; herpes simplex virus (HSV-2); viral shedding reduction; genital lesion reduction; safety profile; Gilead Sciences; collaboration; stock purchase
Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends
Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment
Bayer Layoffs Top 12,000 with More Cuts Expected Amid Ongoing Restructuring
Bayer; layoffs; restructuring; cost-cutting; employee reductions; Bill Anderson; 2025; pharma industry
Praxis touts ‘best-in-disease’ epilepsy data, but shares dip
Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market
Merck to Lay Off 6,000 Employees, Reduce Workforce by 8% in $3B Cost-Cutting Move
Merck; layoffs; cost-cutting; restructuring; pharmaceuticals; job cuts; Keytruda; Gardasil; workforce reduction
Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push
Moderna; layoffs; workforce reduction; cost-cutting; $1.5 billion savings; 2025; Stéphane Bancel; biotechnology; COVID-19 vaccine
Lilly’s Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval
Mounjaro; tirzepatide; Eli Lilly; cardiovascular outcomes; type 2 diabetes; SURPASS-CVOT; Trulicity; dulaglutide; major adverse cardiovascular events (MACE-3); non-inferiority; A1C reduction; weight loss; mortality; FDA expansion
Ignoring China’s Biotech Industry Is No Longer an Option: Recent Developments and Implications
China biotech industry; global drug development; clinical trials; innovation ecosystem; pharmaceutical R&D; biotech patents; US-China competition